KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Evolent Health (EVH) Accounts Payables (2016 - 2025)

Evolent Health (EVH) has 10 years of Accounts Payables data on record, last reported at $72.2 million in Q3 2025.

  • For Q3 2025, Accounts Payables changed N/A year-over-year to $72.2 million; the TTM value through Sep 2025 reached $72.2 million, changed N/A, while the annual FY2024 figure was $96.0 million, 99.03% up from the prior year.
  • Accounts Payables reached $72.2 million in Q3 2025 per EVH's latest filing, down from $96.0 million in the prior quarter.
  • Across five years, Accounts Payables topped out at $96.6 million in Q2 2022 and bottomed at $39.0 million in Q2 2024.
  • Average Accounts Payables over 5 years is $68.1 million, with a median of $64.0 million recorded in 2022.
  • Peak YoY movement for Accounts Payables: tumbled 40.5% in 2022, then soared 99.03% in 2024.
  • A 5-year view of Accounts Payables shows it stood at $96.1 million in 2021, then crashed by 40.5% to $57.2 million in 2022, then decreased by 15.62% to $48.2 million in 2023, then skyrocketed by 99.03% to $96.0 million in 2024, then dropped by 24.83% to $72.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Accounts Payables were $72.2 million in Q3 2025, $96.0 million in Q4 2024, and $39.0 million in Q2 2024.